Latest Breaking News On - வினய் பிரசாத் - Page 5 : comparemela.com
Yves here. This post from Health Care Renewal continues with its discussion of aducanumab, a drug so unlikely to make a material difference to Alzheimer’s victims that absent the mind-blowing price tag (estimated at $56,000 a year), it looks like Big Pharma’s answer to faith healing. It discusses what outcomes are probable, including the grotesque enrichment of its creator, Biogen, at the expense of patients and insurance programs, including Medicare.
In other words, if you think aducanumab isn’t your problem, think twice. Medical-industrial complex grifting is the big reason the US has vastly higher healthcare costs, in percentage of GDP terms, than any other economy, yet has middle of the road to lagging results compared to other advanced economies. Compared to other plays, like private equity employed outsourced hospital staff acting as a vehicle for rent extraction via “surprise billing,” the aducanumab fleece is very easy to understand.
Vinay-prasad
Elizabeth-rosenthal
Janet-woodcock
Health-care-renewal
Big-pharma
Public-citizen
Health-care
Clinical-dementia-rating-sum
Best-case-future
Future-according
வினய்-பிரசாத்
எலிசபெத்-ரோசென்டல்